Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Bioorg Med Chem Lett. 2012 Jan 1;22(1):713-7. doi: 10.1016/j.bmcl.2011.10.041. Epub 2011 Oct 20.
Development of SAR at the C2 position of indole lead 1, a palm site inhibitor of HCV NS5B polymerase (NS5B IC(50)=0.053μM, replicon EC(50)=4.8μM), is described. Initial screening identified an acyl sulfonamide moiety as an isostere for the C2 carboxylic acid group. Further SAR investigation resulted in identification of acyl sufonamide analog 7q (NS5B IC(50)=0.039μM, replicon EC(50)=0.011μM) with >100-fold improved replicon activity.
描述了先导化合物 1 中吲哚 C2 位的 SAR 研究,先导化合物 1 是 HCV NS5B 聚合酶的 palm 位点抑制剂(NS5B IC50=0.053μM,复制子 EC50=4.8μM)。初步筛选确定了酰基磺酰胺部分作为 C2 羧酸基团的等排体。进一步的 SAR 研究确定了酰基磺酰胺类似物 7q(NS5B IC50=0.039μM,复制子 EC50=0.011μM),其复制子活性提高了 100 多倍。